Hoestdrank Broomhexine Hcl Htp

Hoestdrank Broomhexine Hcl Htp is an oral mucolytic medication that contains the active ingredient bromhexine hydrochloride. The product is marketed in the European Union and is supplied in tablet or syrup form, although the exact dosage strength is not specified on the label. As a mucolytic agent, it is intended to help clear thick respiratory secretions in patients with cough or respiratory infections and improve airway patency.

Hoestdrank Broomhexine Hcl Htp is used as a mucolytic to aid the removal of thick mucus from the respiratory tract.

- Cough associated with thick, viscous sputum that is difficult to expectorate. - Acute or chronic bronchitis where mucus accumulation contributes to airway obstruction. - Upper respiratory tract infections in which impaired mucus clearance worsens congestion and discomfort. - Chronic obstructive pulmonary disease (COPD) exacerbations characterized by productive cough and increased sputum volume. - Post‑viral respiratory irritation leading to mucus buildup that may prolong cough duration. - Sinusitis or other ENT conditions where thick secretions hinder normal drainage.

Bromhexine hydrochloride may cause a range of adverse reactions, most of which are mild and reversible.

Common: - Nausea or upset stomach. - Diarrhea or loose stools. - Mild abdominal discomfort. - Taste disturbances or a bitter taste in the mouth. - Skin rash or mild itching. - Dizziness or light‑headed feeling. - Headache.

Serious: - Severe allergic reactions such as anaphylaxis, angioedema, or swelling of the face and throat. - Hepatotoxicity presenting as jaundice or elevated liver enzymes. - Persistent or worsening gastrointestinal bleeding. - Bronchospasm or severe respiratory distress. - Hematologic abnormalities like eosinophilia or neutropenia. - Acute pancreatitis manifested by severe abdominal pain and elevated enzymes. - Renal impairment indicated by reduced urine output or increased creatinine.

When considering bromhexine hydrochloride, certain precautions should be observed to minimize risk and ensure safe use.

- Assess for known hypersensitivity to bromhexine or any excipients before initiating therapy. - Use cautiously in patients with a history of peptic ulcer disease or gastrointestinal bleeding. - Monitor liver function in individuals with pre‑existing hepatic disorders. - Avoid use in severe asthma or active bronchospasm without medical supervision. - Consider dose adjustment or close observation in the elderly or those with renal impairment. - Pregnant or breastfeeding women should consult a healthcare professional before use.

Bromhexine hydrochloride can interact with certain medicines, affecting either its efficacy or the safety profile of the co‑administered drug.

Avoid: - Concomitant use with antitussive agents containing codeine or dextromethorphan, which may mask the therapeutic effect of mucus clearance. - Combination with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) that could increase bromhexine plasma levels. - Use with other mucolytic agents such as N‑acetylcysteine, which may lead to additive effects and gastrointestinal irritation.

Use with caution: - Co‑administration with anticoagulants or antiplatelet drugs, as bromhexine may potentiate bleeding risk. - Concurrent use of bronchodilators (β2‑agonists) may require monitoring for respiratory response. - Patients on antihistamines should be observed for possible increased sedation or drowsiness.